New publication by Gradientech and Uppsala University on rapid AST platform
There is an unmet need for faster and more precise AST methods that can determine which antibiotics will be mast effective against a bacterial infection in a timely man ner. This is particularly important for time-critical conditions like sepsis, where every minute without appropriate treatment reduces the chance of survival.
The results obtained with the multiplex fluidic chip serve as a proof-of-concept for the commercial QuickMIC® AST system that Gradientech is currently developing, which is based on the same proprietary technology. This rapid AST technology has the potential to enable faster and targeted treatment initiation in sepsis patients, thereby contributing to improved clinical outcomes, reduced healthcare costs and help in the fight against antibiotic resistance.
The study findings have been published in mBio, a prestigious open access journal from the American Society for Microbiology. To access the full article, follow the link below: